Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition

被引：6

作者：

Smith, Terry J. ^{[1
,2
]}

机构：

[1] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Sch Med, Brehm Tower,1000 Wall St, Ann Arbor, MI 48105 USA

[2] Univ Michigan, Sch Med, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI USA

来源：

JOURNAL OF NEURO-OPHTHALMOLOGY | 2020年 / 40卷 / 01期

基金：

美国国家卫生研究院;

关键词：

HUMAN ORBITAL FIBROBLASTS; CULTURED HUMAN-FIBROBLASTS; SEVERE GRAVES ORBITOPATHY; THYROTROPIN-RECEPTOR; CIRCULATING FIBROCYTES; HYALURONAN SYNTHESIS; STIMULATING IMMUNOGLOBULINS; MONOCLONAL-ANTIBODY; IGF-1; RECEPTOR; DISEASE INDUCE;

D O I：

10.1097/WNO.0000000000000890

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Thyroid-associated ophthalmopathy (TAO) is an autoimmune component of Graves' disease for which no currently available medical therapy provides reliable and safe benefit. Based on insights generated experimentally over the past several decades, the insulin-like growth factor-I receptor (IGF-IR) has been implicated in the pathogenesis of TAO. Furthermore, an IGF-IR inhibitor, teprotumumab, has emerged from 2 clinical trials as a promising treatment for active, moderate to severe TAO. This brief review intends to provide an overview of the rationale underlying the development of teprotumumab for this disease. It is possible that teprotumumab will soon take its place in our therapeutic armamentarium for active TAO.

引用

页码：74 / 83

页数：10

共 90 条

[1] MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease [J].

Allahabadia, A ;

Heward, JM ;

Nithiyananthan, R ;

Gibson, SM ;

Reuser, TTQ ;

Dodson, PM ;

Franklyn, JA ;

Gough, SCL .

LANCET, 2001, 358 (9286) :984-985

[2] Slit2-mediated chemorepulsion and collapse of developing forebrain axons [J].

Ba-Charvet, KTN ;

Brose, K ;

Marillat, V ;

Kidd, T ;

Goodman, CS ;

Tessier-Lavigne, M ;

Sotelo, C ;

Chédotal, A .

NEURON, 1999, 22 (03) :463-473

[3] Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy [J].

Bartalena, L. ;

Krassas, G. E. ;

Wiersinga, W. ;

Marcocci, C. ;

Salvi, M. ;

Daumerie, C. ;

Bournaud, C. ;

Stahl, M. ;

Sassi, L. ;

Veronesi, G. ;

Azzolini, C. ;

Boboridis, K. G. ;

Mourits, M. P. ;

Soeters, M. R. ;

Baldeschi, L. ;

Nardi, M. ;

Curro, N. ;

Boschi, A. ;

Bernard, M. ;

von Arx, G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (12) :4454-4463

[4] Cigarette smoking: number one enemy for Graves ophthalmopathy [J].

Bartalena, Luigi ;

Piantanida, Eliana .

POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (10) :725-726

[5] Quality of life and neuropsychiatric disorders in patients with Graves' for Orbitopathy: Current concepts [J].

Bruscolini, Alice ;

Sacchetti, Marta ;

La Cava, Maurizio ;

Nebbioso, Marcella ;

Iannitelli, Angela ;

Quartini, Adele ;

Lambiase, Alessandro ;

Ralli, Massimo ;

de Virgilio, Armando ;

Greco, Antonio .

AUTOIMMUNITY REVIEWS, 2018, 17 (07) :639-643

[6] CIRCULATING FIBROCYTES DEFINE A NEW LEUKOCYTE SUBPOPULATION THAT MEDIATES TISSUE-REPAIR [J].

BUCALA, R ;

SPIEGEL, LA ;

CHESNEY, J ;

HOGAN, M ;

CERAMI, A .

MOLECULAR MEDICINE, 1994, 1 (01) :71-81

[7] Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression - Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy [J].

Cao, HJ ;

Wang, HS ;

Zhang, Y ;

Lin, HY ;

Phipps, RP ;

Smith, TJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (45) :29615-29625

[8] Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes [J].

Chen, Hong ;

Mester, Tuende ;

Raychaudhuri, Nupur ;

Kauh, Courtney Y. ;

Gupta, Shivani ;

Smith, Terry J. ;

Douglas, Raymond S. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (09) :E1635-E1640

[9] The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ [J].

Chesney, J ;

Bacher, M ;

Bender, A ;

Bucala, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (12) :6307-6312

[10] Teprotumumab for the Treatment of Active Thyroid Eye Disease [J].

Douglas, R. S. ;

Kahaly, G. J. ;

Patel, A. ;

Sile, S. ;

Thompson, E. H. Z. ;

Perdok, R. ;

Fleming, J. C. ;

Fowler, B. T. ;

Marcocci, C. ;

Marino, M. ;

Antonelli, A. ;

Dailey, R. ;

Harris, G. J. ;

Eckstein, A. ;

Schiffman, J. ;

Tang, R. ;

Nelson, C. ;

Salvi, M. ;

Wester, S. ;

Sherman, J. W. ;

Vescio, T. ;

Holt, R. J. ;

Smith, T. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (04) :341-352

← 1 2 3 4 5 6 7 8 9 →